Intercell AG expects to report data in 2010 on two late-stage vaccine candidates against hospital-acquired infections, conditions that have become serious in recent years because of bacterial resistance to marketed antibiotics.
Intercell AG expects to report data in 2010 on two late-stage vaccine candidates against hospital-acquired infections, conditions that have become serious in recent years because of bacterial resistance to marketed antibiotics.